Compare ARK Genomic Revolution ETF (ARKG) vs Nike Inc (NKE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Nike Inc — how do they compare? ARK Genomic Revolution ETF trades at $41.25, while Nike Inc trades at $44.43 (market cap $65.71B). The key difference: Nike Inc pays a 3.7% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Nike Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | NKE | |
|---|---|---|
Sector | Sector/Thematic | Consumer Cyclical |
52-Week High | $43.57 | $79.24 |
52-Week Low | $23.09 | $40.75 |
Market Cap | — | $65.71B |
Volume | — | 8,887,180 |
Enterprise Value | — | $67.71B |
Dividend Yield | — | 3.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Nike (NKE) trades at $44.37, up 3.72% today, with a bearish technical signal but strong profitability metrics including a 22.14% ROE. Recent earnings have consistently beaten estimates, though revenue declined to $46.31B in 2025. The stock faces headwinds from inventory challenges and softer demand in key markets like China, yet maintains a dominant brand position and analyst consensus price target of $50.67.
The outlook hinges on Nike's turnaround strategy stabilizing earnings amid competitive pressures. Investment opportunity lies in brand strength and digital growth, but risks include margin compression and macroeconomic sensitivity. Wall Street sentiment is mixed with 48.57% buy ratings, reflecting cautious optimism for execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →
